NANGIOTX

NangioTx, Inc. has developed a proprietary injectable drug, V-10, that creates new blood vessels for the treatment of peripheral artery disease (PAD), for which there is currently no FDA-approved therapy. PAD is characterized by poor blood flow to the legs, which leads to tissue damage and ultimately limb amputation/death. V-10’s activity is localized, minimally invasive, reverses the disease, and is cost-efficient. We have secured IP and have "freedom to operate."